Stay updated on Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.

Latest updates to the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse operating-status notice and the previous Revision: v3.4.1.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding and operating status has been added, with guidance to opm.gov for updates. The page now shows a new revision tag (v3.4.1) replacing the previous (v3.4.0).SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a Show glossary toggle and new metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); core study content remains unchanged.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page revision update shows Revision: v3.3.4, replacing the previous v3.3.3; no study details or eligibility information were changed.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page now shows Revision: v3.3.3 and removes HHS Vulnerability Disclosure and Revision: v3.3.2, with no impact to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.